Efficacy and safety of two antihyperglycaemic agents (NCT00622284) and a DPP4-inhibitor (BI1245.19; NCT01131676)

Study objectives:

To compare the efficacy and safety of two different SGLT2-inhibitors (BMI ≤45kg/m² and ≤10% body weight change) in patients with T2D.

Secondary objectives:

To compare the efficacy and safety of two different SGLT2-inhibitors (BMI ≤45kg/m² and ≤10% body weight change) in patients with T2D.

Inclusion criteria:

Patients aged 18 to 75 years old, with estimated glomerular filtration rate (eGFR) ≥50mL/min at screening/placebo run, with a body mass index (BMI) ≤45kg/m² and a body weight change ≤10% in the previous 6 months.

Exclusion criteria:

Patients with any acute or chronic condition that would jeopardise patient safety while participating in this clinical trial.

Study design:

Randomised, double-blind, placebo-controlled, parallel-group, 52-week, multicentre, International, 2-arm, 1:1, open-label, investigator-initiated study (NCT01106677).

Study population:

Patients with T2D, with a baseline HbA1c ≥7% and ≤9% (BMI ≥22 kg/m²), with a body weight ≥80 kg (men) or ≥70 kg (women).

Study endpoints:

Primary endpoint: Change in HbA1c from baseline to 26 weeks.

Secondary endpoints:

1. Change in FPG from baseline to 26 weeks.
2. Change in CV risk factors from baseline to 26 weeks.
3. Change in safety laboratory parameters from baseline to 26 weeks.

Study duration:

February 2009 to February 2011 (core period) and/or March 2010 to February 2011 (core period) (NCT00622284).

Participants:

Patients with a previous history of cardiovascular disease (MI, unstable angina, revascularisation procedure or cerebrovascular accident) and those who have had an unstable or acute coronary syndrome, stroke, TIA within 2 months.

Safety:

No significant differences were observed in the safety profile of the two antihyperglycaemic agents compared to placebo.

Conclusion:

Both SGLT2-inhibitors were well tolerated and demonstrated comparable efficacy in reducing HbA1c levels in patients with T2D, with a BMI ≤45kg/m² and a body weight change ≤10% in the previous 6 months.

Note: Results from this study have been published elsewhere.